At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Pumitamig (drug), Ipilimumab (drug)
- How long the study runs
- Study runs about 67 months (dates as stated)
- About the drug or intervention
- Pumitamig — drug: Specified dose on specified days · Ipilimumab — drug: Specified dose on specified days
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 198
- Started
- 2026-03-16
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for hepatocellular carcinoma (hcc)
- • Phase1/Phase2 - 198 participants
- • The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with hepatocellular carcinoma (hcc)
Where?
- • London - Hammersmith Hospital
- • Glasgow - Cancer Research UK - The Beatson Institute for Cancer Research (Cancer Research UK Beatson Laboratories)
- • Metropolitan Borough of Wirral - The Clatterbridge Cancer Centre
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Treatment history
Treatments you must have had:
- ✓ an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- ✓ no prior systemic therapy for advanced/ unresectable HCC
- ✓ measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1
What the study is looking for
- ✓Inclusion Criteria
- ✓Participants must have a confirmed by a biopsy diagnosis of that has grown locally or unresectable Hepatocellular...
- ✓Participants must have an activity scale (ECOG) performance status of 0 or 1.
- ✓Participants must have no prior treatment that goes through your whole body for advanced/ unresectable HCC.
- ✓Participants must have cancer that can be measured on scans as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
See the full criteria
Where Is This Study? (3 UK sites)
Hammersmith Hospital
London W12 0HS, United Kingdom
Cancer Research UK - The Beatson Institute for Cancer Research (Cancer Research UK Beatson Laboratories)
Glasgow G611BD, United Kingdom
The Clatterbridge Cancer Centre
Metropolitan Borough of Wirral CH63 4JY, United Kingdom
How to Get in Touch
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Sponsor contactCONTACT
First line of the email MUST contain NCT # and Site #.
Sponsor contactCONTACT